2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4249 CMV-specific immune reconstitution, rather than gvhd prophylaxis strategy, is associated with CMV risk after haploidentical HCT in the letermovir era

Luxiang Wang, Su Li2, Chuanhe Jiang3, Zilu Zhang, MD4, Jiayu Huang, MD5, Haiyang LU6, Zengkai Pan7, Yang Cao, MD8, Xiaoxia Hu, MD9
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
2 Department of Hematology, Liquan Hospital, GoBroad Medical Institute of Hematology (Shanghai Center), shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China, Wuhan, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine shanghai, China, shanghai, China

Background

Letermovir prophylaxis has reduced cytomegalovirus (CMV) complications after haploidentical hematopoietic cell transplantation (HCT); however, breakthrough clinically significant CMV infection (cs-CMVi) remains common after prophylaxis discontinuation. As graft-versus-host disease (GvHD) prophylaxis strategies differentially modulate donor-derived immune recovery, whether post-transplant cyclophosphamide (PTCY) versus anti-thymocyte globulin (ATG) influences CMV-specific immune reconstitution and subsequent CMV risk remains unclear. We hypothesized that CMV-CMI, rather than GvHD prophylaxis strategy itself, represents the key biological determinant of CMV protection after haploidentical HCT.

Methods

We analyzed 374 CMV-seropositive recipients undergoing first haploidentical HCT between January 2023 and October 2025. GvHD prophylaxis consisted of ATG-based regimens (n = 284; ATG 7.5 mg/kg administered on days −4 to −2) or PTCY-based regimens (n = 90; cyclophosphamide 50 mg/kg on days +3 and +4). CMV-CMI was assessed by CMV-ELISpot, with reconstitution defined as IE-1 specific T cells ≥50 and/or pp65 specific T cells ≥100 spot-forming cells per 2.5×106 peripheral blood mononuclear cells. 69.4% (197/284) in ATG group and 77.8% (70/90) in PTCY group received CMV-CMI testing as scheduled. The primary endpoint was 1-year cumulative incidence of cs-CMVi. Secondary endpoints included CMV-CMI reconstitution kinetics, CMV disease, refractory/resistant (R/R) CMV infection, late-onset cs-CMVi (defined after letermovir discontinuation) and GvHD outcomes. Overlap propensity-score and inverse-probability-of-testing weighting addressed informative CMV-CMI missingness and baseline imbalance. Competing-risk analysis, propensity-score weighting, landmark analysis, and time-dependent modeling were performed.

Results

Among 374 recipients, baseline characteristics differed between groups, with PTCY recipients being younger and receiving higher CD34+ cell doses; these imbalances were addressed by overlap weighting, with all standardized mean differences < 0.10 after adjustment. The 1-year cumulative incidence of cs-CMVi was comparable between ATG and PTCY-based GvHD prophylaxis groups (21.7% vs. 20.2%; P = .59) , with similar median time to CMV infection (140 vs. 133 days; P = .31). The incidences of CMV disease and R/R CMV infection were also comparable between groups.

GvHD prophylaxis strategy did not significantly alter the kinetics of CMV-specific immune reconstitution. The 90-day cumulative incidence of CMV-CMI reconstitution was 44.2% in the ATG group and 51.4% in the PTCY group (P = .10), and this difference remained nonsignificant after overlap weighting (subdistribution HR, 1.16; 95% CI, 0.87–1.55; P = .31). These findings indicate that the choice of GvHD prophylaxis platform does not independently determine CMV-specific immune recovery.

In contrast, CMV-CMI recovery emerged as a predictor of subsequent antiviral protection. In a day-90 landmark analysis, patients achieving CMV-CMI reconstitution had a significantly lower risk of subsequent cs-CMVi (adjusted subdistribution HR, 0.42; 95% CI, 0.22–0.81; P = .01), and this protective association was consistent across ATG- and PTCY-based prophylaxis (CMV-CMI × prophylaxis interaction, P = .86). Among CMV-CMI evaluable patients, CMV-CMI recovery was also associated with reduced risk of late-onset cs-CMVi after letermovir discontinuation (subdistribution HR, 0.47; 95% CI, 0.25–0.91; P = .02). Notably, PTCY was associated with a higher incidence of moderate-to-severe chronic GvHD (25.6% vs. 13.3%; adjusted subdistribution HR, 2.03; P = .04), whereas overall survival, relapse, non-relapse mortality, and acute GvHD were comparable between groups.

Conclusions

In the letermovir era, GvHD prophylaxis strategy with PTCY versus ATG does not independently alter CMV-specific immune reconstitution or breakthrough CMV infection after haploidentical HCT. Instead, CMV-CMI recovery represents a prophylaxis-independent biomarker of antiviral immune protection, particularly against late-onset cs-CMVi after letermovir discontinuation. These findings support incorporation of immune reconstitution monitoring into future risk-adapted CMV prevention strategies.

Luxiang Wang: No relevant conflicts of interest to declare.